Syed Mujtaba Ali Naqvi

Assistant Professor

University of Arkansas for Medical Sciences

faculty

COM | Internal Med Hem-Onc

7 h-index 38 pubs 282 cited

Research Areas

Advanced biosensing and bioanalysis techniques Machine learning-driven analysis Nanoparticles: synthesis and applications Multiple Myeloma Research and Treatments Environmental monitoring Cancer Treatment and Pharmacology Health Sciences Research and Education Meta-analysis and systematic reviews

Links

ORCID Lab Website Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Syed Mujtaba Ali Naqvi's research interests encompass multiple areas, including the development of advanced sensing technologies for environmental monitoring and the investigation of machine learning applications in scientific analysis. His work has explored the adsorption capabilities of magnetic biochar for nano/microplastics and the creation of fluorescence-based sensors for hazardous molecules. Additionally, Naqvi has contributed to research in hematology-oncology, specifically investigating treatment outcomes for patients with relapsed/refractory multiple myeloma and exploring the use of machine learning for predicting the performance of electrocatalysts. He has also published on medical case studies, including postpartum HELLP syndrome complicated with a liver hematoma. Naqvi's scholarly output includes 38 publications and 282 citations, with an h-index of 7. He collaborates with researchers at the University of Arkansas for Medical Sciences, including Hira Imad Cheema, Trilok Shrivastava, Ramya Bachu, and Tanvi H Patel.

Metrics

h-index: 7
Publications: 38
Citations: 282

Selected Publications

Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network. (2025) DOI
Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network. (2025) DOI
Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors (2025) DOI
Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition (2025) DOI
Discontinuation of levothyroxine therapy in patients with subclinical hypothyroidism: a pilot randomized clinical trial (2025) DOI
Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab (2024) DOI
Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma. (2024) DOI
SAT145 Familial Renal Glycosuria - A Differential Diagnosis For Hypoglycemia (2023) DOI
THU664 Discontinuation Of Low-dose Levothyroxine Therapy For Patients With Subclinical Hypothyroidism Is Feasible: A Pilot, Randomized, Double-blind, Placebo-controlled Trial (2023) DOI
SAT173 Insulin Autoimmune Syndrome: A Rare Diagnosis With Unique Features (2023) DOI
Self-expanding metal stents for the treatment of malignant colon obstruction from extra-colonic malignancy versus intra-colonic malignancy: a systematic review and meta-analysis (2023) DOI
Overtreatment and Undertreatment with Thyroid Hormone Is Associated with Cardiovascular Mortality (2022) DOI